FY2028 Earnings Forecast for CLDX Issued By Leerink Partnrs

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Stock analysts at Leerink Partnrs reduced their FY2028 earnings per share estimates for shares of Celldex Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical company will post earnings per share of $0.99 for the year, down from their prior estimate of $1.04. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ FY2029 earnings at $6.67 EPS.

Several other equities analysts have also issued reports on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Celldex Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Trading Up 3.6 %

Shares of NASDAQ CLDX opened at $23.99 on Thursday. The stock has a 50 day moving average price of $25.40 and a 200 day moving average price of $30.72. Celldex Therapeutics has a 52-week low of $22.17 and a 52-week high of $53.18.

Hedge Funds Weigh In On Celldex Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CLDX. Wellington Management Group LLP lifted its position in Celldex Therapeutics by 14.5% during the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after buying an additional 1,167,659 shares during the period. Bellevue Group AG boosted its stake in Celldex Therapeutics by 3.4% in the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock valued at $104,404,000 after acquiring an additional 100,000 shares during the period. Geode Capital Management LLC grew its stake in Celldex Therapeutics by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock worth $52,372,000 after buying an additional 6,557 shares during the last quarter. Jennison Associates LLC grew its position in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after purchasing an additional 321,325 shares during the last quarter. Finally, Novo Holdings A S boosted its position in shares of Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock worth $32,755,000 after buying an additional 113,663 shares during the period.

Insider Buying and Selling

In other Celldex Therapeutics news, CEO Anthony S. Marucci acquired 11,500 shares of the business’s stock in a transaction on Monday, November 11th. The stock was purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now owns 40,284 shares of the company’s stock, valued at $1,080,416.88. The trade was a 39.95 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is owned by company insiders.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.